evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

Loratadine 10 mg vs placebo (4‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

1 finding from 1 review

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema

Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).

1 finding from 1 review

Loratadine 10 mg vs placebo (2‐week intervention)

Secondary outcome 1. Physician‐assessed clinical signs Number for whom treatment success was judged as good or very good · adults with eczema

Loratadine 10 mg/d showed no clear difference in secondary outcome 1. Physician‐assessed clinical signs Number for… compared with placebo (2‐week intervention) (low certainty).

1 finding from 1 review

Cetirizine 10 mg/d vs placebo (4‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

1 finding from 1 review

Quinolone vs macrolides

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review